Immunophotonics is excited to be featured in Pharma Tech Outlook magazine in the Immunotherapy edition. Immunophotonics innovative approach could transform standard treatments into powerful immunotherapies with IP-001 turning every procedure into an opportunity to mobilize the body’s natural immune system against cancer. “A New Frontier in Treating Cancer: The Great Potential of Interventional Immuno-Oncology™ Link...
Immunophotonics is excited to announce that a leading academic medical center that combines high-quality complex patient care with innovative scientific research, received authorization to proceed with recruitment to conduct a clinical trial combining Immunophotonics’ investigational drug IP-001 with AngioDynamics’ advanced ablation devices. This trial will explore the power of IP-001 following thermal ablation or irreversible...
Lu Alleruzzo, CEO, Tomas Hode, PhD, CIO, and President, along with the Immunophotonics Team, extend their congratulations to Professor Wei Chen, co-inventor of IP-001, for being honored as one of the Class of 2024 Senior Members by the National Academy of Inventors (NAI). Professor Chen is getting recognized for his significant contributions to biomedical engineering...
Immunophotonics is excited to share that Dr. Robert CG Martin II, M.D, PhD, PACS, who serves as Principal Investigator and National Coordinating Investigator at the University of Louisville for Immunophotonics’ Phase 2 clinical trial, will be presenting his IRE data at the Central Surgical Association 81st Annual Meeting taking place June 6 – 8, 2024,...
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Chicago at the ASCO (American Society of Clinical Oncology) annual meeting, May 31 – June 3, 2024, taking place at the McCormick Place convention center. They are thrilled to engage with clinical experts worldwide, explore cutting-edge research, and discover innovative...
Immunophotonics, Inc. is delighted to introduce Jacqueline Hess as the newest addition to our advisory board. Ms. Hess has over 25 years of Big 4 experience supporting U.S. biotech companies that are expanding globally, with a particular focus on the U.S.-Swiss business corridor. Jacqueline is dedicated to helping life sciences companies thrive and achieve their mission of helping...
Tomas Hode, PhD, who serves as the Co-Founder, CIO, and President at Immunophotonics, Inc., will be attending the European Conference on Interventional Oncology (ECIO 2024) in Palma de Mallorca, Spain, from April 28-May 1. To learn more about how Immunophotonics continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into a...
Immunophotonics is thrilled to share that Dr. Theresa Visarius from Immunophotonics Switzerland (IPS Biopharma) will be attending the Swiss Biotech Day 2024 in Basel, Switzerland, on April 22 – 23. Joining her will be our new Immunophotonics advisor, Jacqueline Hess. Don’t miss her poster presentation showcasing how Immunophotonics is advancing the novel concept of abscopalizing...
Tomas Hode, PhD, who serves as the Co-Founder, CIO, and President at Immunophotonics, Inc. is eager to attend the AngioDynamics International Life Symposium “The Human Touch, Behind Innovation” scheduled for March 21-23 in Rome. At this event, he will be engaging with clinical experts and industry partners on the latest technologies for surgical interventions.
Immunophotonics to be showcased as the Member Highlight for March by The Missouri Biotechnology Association (MOBIO), both on their homepage and in the March newsletter. MOBIO serves as a representative body for all Missouri entities engaged in life sciences, innovation, and entrepreneurship, promoting advancements in life science research, and fostering economic development. This recognition provides...
